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The b2-adrenoceptor (b2AR) was one of the ﬁrst Family AG
protein-coupled receptors (GPCRs) shown to form oligo-
mers in cellular membranes, yet we still know little about
the number and arrangement of protomers in oligomers,
the inﬂuence of ligands on the organization or stability of
oligomers, or the requirement for other proteins to pro-
mote oligomerization. We used ﬂuorescence resonance
energy transfer (FRET) to characterize the oligomerization
of puriﬁed b2AR site-speciﬁcally labelled at three different
positions with ﬂuorophores and reconstituted into a model
lipid bilayer. Our results suggest that the b2AR is predo-
minantly tetrameric following reconstitution into phos-
pholipid vesicles. Agonists and antagonists have little
effect on the relative orientation of protomers in oligo-
meric complexes. In contrast, binding of inverse agonists
leads to signiﬁcant increases in FRET efﬁciencies for most
labelling pairs, suggesting that this class of ligand pro-
motes tighter packing of protomers and/or the formation
of more complex oligomers by reducing conformational
ﬂuctuations in individual protomers. The results provide
new structural insights into b2AR oligomerization and
suggest a possible mechanism for the functional effects
of inverse agonists.
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Introduction
The majority of physiological responses to hormones and
neurotransmitters are mediated by G protein-coupled recep-
tors (GPCRs). These integral membrane proteins relay signals
elicited by an array of structurally diverse agonists including
photons, ions, small organic compounds, peptides, proteins
and lipids (Hill, 2006). GPCRs have been classically described
as monomeric transmembrane receptors that form a ternary
complex: a ligand, the GPCR, and its associated G protein
(Chabre and le Maire, 2005; Fung et al, 1981). This classical
view is compatible with observations that monomeric rhodop-
sin and b2-adrenoceptor (b2AR) are capable of activating G
proteins (Bayburt et al, 2007; Ernst et al, 2007; Whorton et al,
2007). Nevertheless, it is now well accepted that Family C
GPCRs are constitutive dimers (Jones, et al, 1998; Margeta-
Mitrovic et al, 2000; Galvez et al, 2001), and many Family A
GPCRs have been observed to oligomerize in cells. This was
initially shown for the b2AR in 1996 (Hebert et al, 1996), and
was later followed by publications demonstrating both homo-
and hetero-oligomerization ofab r o a ds p e c t r u mo fF a m i l yA
GPCRs using a variety of techniques (Jordan and Devi, 1999;
Angers et al, 2000; Gines et al, 2000; Rocheville et al, 2000;
Cheng and Miller, 2001; Mellado et al, 2001; Latif et al,2 0 0 2 ;
Salahpour et al, 2004; Gonzalez-Maeso et al, 2008; Guo et al,
2008; Vilardaga et al,2 0 0 8 ) .D e s p i t et h i se v i d e n c e ,t h ee f f e c to f
ligands on formation, organization and stability of receptor
oligomers, as well as the role of other cellular proteins, is not
well understood and may be receptor subtype speciﬁc (Angers
et al, 2000; Cheng and Miller, 2001; Latif et al,2 0 0 2 ;Z h uet al,
2002; Roess and Smith, 2003; Law et al,2 0 0 5 ) .
High-resolution crystal structures are now available for the
inactive state of the b2AR (Cherezov et al, 2007; Rasmussen
et al, 2007; Rosenbaum et al, 2007); yet, we still know very
little about the structure, stoichiometry and dynamics of
oligomers in lipid bilayers. To date, much of what is known
about oligomerization of b2ARs and other Family A GPCRs
comes from elegant studies using intermolecular ﬂuores-
cence/bioluminescence resonance energy transfer (FRET or
BRET) in live cells (Angers et al, 2000; Salahpour et al,
2004; Milligan and Bouvier, 2005). In an effort to complement
these cell-based studies and better understand the process of
GPCR oligomerization and the organization of protomers
within oligomers, we investigated oligomerization of puriﬁed
b2AR in a model membrane system. By site speciﬁcally
labelling puriﬁed monomeric b2AR and reconstituting it into
lipid vesicles, we are able to show that this receptor effec-
tively forms speciﬁc multimeric assemblies in lipid bilayers
as monitored by FRETand cross-linking studies. FRETsatura-
tion studies are most consistent with the formation of
tetramers, and differences in FRET between different label-
ling pairs allow us to propose a model of the orientation
of the protomers within the tetramer. An agonist and
neutral antagonist have little effect on b2AR oligomerization,
but the inverse agonist ICI 118,551 promotes rearrangement
of the protomers and/or the formation of higher-order
oligomers.
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Site-speciﬁc labelling of puriﬁed monomeric b2AR and
reconstitution into lipid vesicles
The goal of our studies was to monitor self-association of
b2AR following reconstitution in lipid vesicles and to obtain
information about the relative orientation of protomers in
oligomers. FRET using small-molecular-weight ﬂuorescent
probes is an ideal tool for these studies because it provides
relative distance information yet requires relatively small
amounts of protein (Mansoor et al, 2006). To achieve site-
speciﬁc labelling of the b2AR, we generated modiﬁed recep-
tors having single-reactive cysteines that can be chemically
modiﬁed with sulphydryl-reactive ﬂuorophores. Mutants
were made on a minimal cysteine background in which the
ﬁve chemically reactive cysteines, out of 13, were mutated
(see section Materials and methods). These mutations have
no effect on ligand binding or G protein coupling. The
remaining three cysteines that are not palmitoylated or are
part of disulphide bonds are not reactive due to their location
in the hydrophobic core (Figure 1A). We initially constructed
18 single-cysteine mutants in the cytoplasmic domains of the
receptor. Three were chosen based on their functional proper-
ties, chemical reactivity and their distribution (Figure 1B):
D5-T66C (intracellular loop-1, ICL1), D5-A265C (trans-
membrane domain-6, TM6) and D5-R333C (helix-8, H8)
(Cherezov et al, 2007; Rasmussen et al, 2007; Rosenbaum
et al, 2007). This spatial distribution of the labelling sites was
designed to provide information about the orientation of
protomers relative to each other.
Modiﬁed receptors were expressed in Sf9 cells using
recombinant baculovirus and puriﬁed using sequential anti-
body and alprenolol afﬁnity chromatography. We have
shown previously that this puriﬁcation protocol produces
monomeric, detergent-solubilized b2AR (Whorton et al,
2007). Puriﬁed, detergent-solubilized b2AR was labelled
with Cy3 or Cy5 maleimide. These ﬂuorophores were chosen
for FRET studies because they possess an R0 value (Fo ¨rster
critical distance where 50% of energy transfer occurs) in the
range of 37 to 56A ˚ depending on the experimental system
(Mansoor et al, 2006; Massey et al, 2006). This is ideal for
studying receptor–receptor interactions since a monomer has
approximate dimensions of 30A ˚  40A ˚  70A ˚. b2ARs were
labelled with stoichiometric amounts of either Cy3 or Cy5,
and the efﬁciency of labelling was determined by absorption
spectroscopy (Supplementary Table I). Labelled b2AR was
reconstituted into a mixture of 1,2-dioleoyl-sn-glycero-3-
phosphocholine (DOPC) and cholesterol hemisuccinate
(CHS) lipids. Three samples were generated for each experi-
ment: (1) reconstituted Cy3-labelled b2AR; (2) reconstituted
Cy5-labelled b2AR and (3) Cy3-labelled b2AR mixed with
Cy5-labelled b2AR and then reconstituted. The ﬁnal lipid-to-
receptor molar ratio (mol-to-mol) was 1000:1 unless other-
wise indicated. The same samples were prepared for controls,
but were maintained in 0.1% DM and not reconstituted
into vesicles.
Orientation of b2AR in lipid vesicles
Knowing the orientation of b2AR in our lipid vesicles is
essential for interpreting FRET measurements. Random or-
ientation would generate potential non-physiological
(antiparallel) oligomers. While random orientation might be
expected, previous studies have shown that rhodopsin ori-
ents predominantly in one direction following reconstitution
(Niu et al, 2002). We used several complementary strategies
to determine the orientation of b2AR in phospholipid vesicles
(Figure 2A). Factor Xa is a protease that selectively cleaves
the b2AR within the third ICL (ICL3). Receptors oriented
inside-out (ICL3 outside of lipid vesicle) will be susceptible
to Factor Xa, whereas those oriented outside-out will not
(Figure 2A). Approximately 90% of reconstituted b2AR was
Cy3 maleimide (donor) Cy5 maleimide (acceptor)
TM6
(A265C) H8
(R333C)
ICL1
(T66C)
TM1
TM2
TM4
TM3
TM5
TM7
Figure 1 b2AR single-cysteine constructs and FRET donor–acceptor pair. (A) Three single-reactive cysteines constructs were generated on a
minimal cysteine background (D5-b2AR). The labelling sites were placed in the ﬁrst ICL, D5-b2AR-T66C, at the cytoplasmic end of the sixth
transmembrane segment, D5-b2AR-A265C, and helix eight, D5-b2AR-R333C. (B) Intracellular 3D view of the distribution of regions chosen for
single-cysteine mutants, a-carbons are depicted. (C) FRET donor (lex¼549nm; lem¼570nm) and acceptor pair (lex¼650nm; lem¼670nm).
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cleaved in the presence of 0.1% DM (Figure 2B), a concen-
tration of detergent, which permeabilizes the vesicles. These
results are consistent with a predominantly outside-out or-
ientation. PNGase F is an enzyme that cleaves asparagine-
linked oligosaccharides on the extracellular N-terminus
(Figure 2A). Treatment of reconstituted receptor with
PNGase F led to a mobility shift that was indistinguishable
from that observed in the presence of 0.1% DM, consistent
with predominantly outside-out orientation (Figure 2C). The
orientation was further conﬁrmed using NHS-PEO4-biotin to
chemically modify the N-terminus (Figure 2A). This polar
compound would not be expected to cross the lipid bilayer.
Chemical modiﬁcation of the N-terminal FLAG epitope results
in loss of reactivity to the M1 antibody; treatment of vesicles
following reconstitution resulted in the loss of M1 reactivity
for more than 90% of reconstituted b2AR (Figure 2D and E).
Finally, we labelled A265C on the cytoplasmic side of the
b2AR with monobromobimane (mBBr) and examined the
ability of tryptophan in solution to quench bimane ﬂuores-
cence. We observed no quenching of reconstituted, bimane-
labelled b2AR with 1mM tryptophan. However, solubilization
of vesicles using 0.2% DM resulted in signiﬁcant quenching
(Supplementary Figure 1). Taken together, these studies show
that the b2AR is predominantly oriented with the extracellular
domains on the outside of the vesicle.
Distribution of b2AR in lipid vesicles
In studying oligomerization, it is important to avoid forcing
protein together by inhomogeneous reconstitution, that is,
trapping the majority of the receptor molecules in a minor
population of lipid vesicles. For instance, it has been shown
previously that 90% of rhodopsin molecules were incorpo-
rated into only 10% of vesicles (Mansoor et al, 2006). We
used isopycnic density centrifugation to assess the distribu-
tion of b2ARs in lipid vesicles as previously described for
rhodopsin (Mansoor et al, 2006). Cy5-labelled b2ARs were
reconstituted at a lipid-to-receptor ratio of 1000:1 in lipids
containing NBD–phosphocholine (at a ﬁnal of 0.4% of total
lipid content). This allowed us to analyze samples subjected
to a discontinuous sucrose density gradient by following Cy5
ﬂuorescence (for the presence of b2AR) and NBD ﬂuores-
cence (for the presence of lipid vesicles). Our results show
nearly perfect correlation between Cy5 ﬂuorescence and NBD
ﬂuorescence at every fraction analyzed, suggesting that b2AR
molecules are uniformly distributed in these vesicles
(Figure 3A). Similar results were obtained with b2AR recon-
stituted at a 10000:1 lipid-to-receptor ratio (Supplementary
Figure 2).
To assess the density of b2ARs in the lipid vesicles, we used
electron microscopy to determine the average diameter of our
b2AR-containing lipid vesicle preparations. Using a negative
staining protocol, we determined that the average diameter of
our vesicle preparations at a lipid-to-receptor ratio of 1000:1
was 83nm±12nm (Figure 3B). Using the calculations de-
tailed in the Supplementary Materials and methods section,
we concluded that there are 50–60 b2ARs per lipid vesicle,
with the majority oriented in an outside-out manner.
Functional characterization of b2AR in lipid vesicles
We performed saturation binding on puriﬁed, reconstituted
receptor to determine the afﬁnity of all three single-cysteine
mutants for the antagonist [
3H]-dihydroalprenolol (DHA). We
observed no signiﬁcant difference between the three modiﬁed
b2ARs and wild-type b2ARs (Table I and Supplementary
Figure 3). Competition binding studies with [
3H]-DHA were
used to determine the Ki values for the agonist isoproterenol
(Iso) and the inverse agonist ICI 118,551 (ICI). As shown in
Table I and Figure 4, the values for the single-cysteine
mutants are comparable to those obtained for wild-type
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Figure 2 b2ARs are predominantly oriented outside-out in lipid bilayers. (A) Strategies for determining orientation of b2AR in lipid bilayers.
(B) Puriﬁed receptors were reconstituted as described under Materials and methods and then subjected to treatment with Factor Xa and
resolved by 10% SDS–PAGE and transferred onto nitrocellulose. The presence of b2AR was determined by probing with an M1 antibody
conjugated with Alexa-680. (C) Samples subjected to PNGase F were prepared and imaged as in panel A. (D, E) Reconstituted samples were
treated with the hydrophilic, amine-reactive, alkylating reagent NHS-PEO4-biotin that disrupts binding of the M1 monoclonal antibody to the
FLAG epitope. Samples were assessed for reactivity to M1 antibody (D) and an antibody that recognizes the C-terminal six-histidine tag (E).
All data are representative of three independent experiments.
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cysteines and reconstitution of puriﬁed b2AR into lipid
vesicles does not alter the pharmacology of the receptor.
Functionality for G protein coupling of the three single-
cysteine mutants was addressed by [
35S]-GTPgS binding. This
assay involves reconstituting puriﬁed b2AR with puriﬁed
Tet-Gas as previously described (Swaminath et al, 2005;
Granier et al, 2007). Agonist binding to all three b2AR
single-cysteine mutants led to signiﬁcant stimulation of G
protein coupling that was similar to wild-type receptor
(Figure 4C). Treatment of samples with the inverse agonist
ICI led to decreases in basal activity similar to that observed
for wild-type receptor (Figure 4C). Modiﬁcation of the single
cysteines with Cy5–maleimide ﬂuorophore had no signiﬁcant
effect on G protein coupling (Figure 4C; P40.05).
FRET analysis of ﬂuorophore-labelled b2ARs in lipid
bilayers
We ﬁrst determined FRET between receptors labelled at the
same position. D5-A265C labelled with Cy3 was reconstituted
with an equivalent amount of D5-A265C labelled with Cy5 in
order to monitor TM6/TM6 interactions. This was repeated
for D5-T66C and D5-R333C, as reporters for ICL1/ICL1 and
H8/H8 interactions, respectively. Figure 5A shows an exam-
ple of a typical experiment performed on D5-T66C. FRET
between Cy3- and Cy5-labelled receptors (30.3±1.2%) is
only observed after receptor reconstitution into a lipid bi-
layer, but not when receptors remain solubilized in detergent
(Figure 5A and Table II). Similar observations were made for
Cy3- and Cy5-labelled D5-A265C (16.7±1.3%) and for Cy3-
and Cy5-labelled D5-R333C (26.9±0.8%; Table II).
To provide additional information about the relative or-
ientation of b2AR protomers, we investigated FRET between
different labelling sites. For example, D5-T66C labelled with
Cy3 was reconstituted with an equivalent amount of
D5-A265C labelled with Cy5 in order to examine ICL1/TM6
interactions. The same approach was followed for the other
possible combinations, ICL1/H8 and TM6/H8 (Table II). The
observation of different FRET efﬁciencies for different label-
ling pairs suggests a speciﬁc arrangement of receptors in the
lipid bilayers rather than nonspeciﬁc aggregation. To further
rule out the possibility that the FRET observed in these
studies is simply due to crowding of labelled receptors at
the lipid bilayer, a 10-fold higher molar concentration of lipids
(a ﬁnal lipid-to-receptor ratio of 10000:1) was used in order
to reduce the number of receptors per unit area of lipid
bilayer. FRET efﬁciencies observed at a lipid-to-receptor
ratio of 10000:1 were not signiﬁcantly different from those
obtained at a ratio of 1000:1 (Figure 5B–D; P40.05).
FRET saturation of ﬂuorophore-labelled b2AR oligomers
To further investigate the speciﬁcity of the observed oligo-
merization, as well as the stoichiometry of the oligomers, we
performed FRET saturation experiments where the ratio of
acceptor ﬂuorophore (Cy5-labelled b2AR) to donor ﬂuoro-
phore (Cy3-labelled b2AR) is increased, while maintaining
the overall receptor concentration and lipid-to-receptor ratio
constant. If the energy transfer is due to speciﬁc receptor–
receptor interactions, FRET efﬁciency will saturate as the
Cy5/Cy3 ratio is increased. In contrast, random collisions
should yield a quasi-linear relationship (Mercier et al, 2002;
James et al, 2006; Harikumar et al, 2008). We observe FRET
saturation for all three b2AR labelling sites (Figure 6A–C),
demonstrating the speciﬁc nature of the interactions.
In addition, FRET saturation can provide insight into the
number of protomers per oligomer. Our FRET saturation
results were compared with a well described mathematical
model (Veatch and Stryer, 1977; Mercier et al, 2002; James
et al, 2006; Harikumar et al, 2008; Harding et al, 2009) that
Table I Agonist, antagonist and inverse agonist binding properties
for the single-reactive cysteine receptors
a
b2AR Ki [s.e. interval] (nM) Kd±s.e.m.
Mutant ( )-Isoproterenol ICI 118,551 [
3H-DHA]
Wild type 355 [203–620] 1.17 [0.77–1.77] 1.3±0.16
D5-T66C 388 [319–473] 2.09 [1.86–2.35] 1.8±0.21
D5-A265C 298 [255–348] 1.84 [1.45–2.33] 2.5±0.23
D5-R333C 214 [168–273] 1.90 [1.59–2.27] 2.4±0.24
aSaturation and competition binding were performed as described
under Materials and methods. Data represent the mean±s.e.m. of
at least three independent experiments.
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Figure 3 b2ARs are homogenously distributed in lipid vesicles. (A) To determine the distribution of b2ARs in lipid vesicles, sucrose density
gradients of samples containing 0.4% NBD–phosphocholine and Cy5–b2ARs reconstituted at a lipid-to-receptor ratio of 1000:1 were performed
as described in the Supplementary data. Detection of lipid fractions was performed by following NBD ﬂuorescence (lex¼460nm) and receptor
fractions by following Cy5 ﬂuorescence (lex¼649nm). (B) Reconstituted b2ARs were imaged using a negative staining protocol as described in
the Supplementary data to determine the size distribution of vesicles and the number of receptors per vesicle. Scale bar length represents
200nm. Data are representative of three independent experiments.
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Figure 4 Single-reactive cysteine mutants are fully functional. The afﬁnity of the agonist isoproterenol (A) and the inverse agonist ICI 118,551
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Figure 5 Intermolecular FRET between Cy3- and Cy5-labelled b2AR is independent of other cellular proteins and is speciﬁc. (A) Puriﬁed,
detergent-solubilized receptor protein was labelled with Cy3 or Cy5 maleimide and unreacted ﬂuorophore was quenched with cysteine and
separated from protein by gel ﬁltration as described under Materials and methods. Cy3- and Cy5-labelled protein samples were mixed at a 1:1
molar ratio and reconstituted into phospholipids bilayers or maintained in detergent. Subtraction of the proper controls and normalization of
the raw traces is described in the Supplementary data. Labelled b2ARs were reconstituted at a 10-fold higher lipid-to-receptor ratio (10000:1)
and FRET efﬁciency was measured for ICL1/ICL1 (B), TM6/TM6 (C) and H8/H8 (D) interactions. Data are representative of at least three
independent experiments (A) or represent the mean±s.e.m. of at least three independent experiments (B–D).
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expected in energy transfer saturation experiments (FRET or
BRET) for dimers, trimers, tetramers, etc. It follows that
saturation will occur at a lower acceptor/donor ratio for
higher-order oligomers than for simple dimers. We normal-
ized our FRET saturation data for all three constructs and
compared them with models for dimers, trimers, tetramers
and higher-order oligomers (eight protomers), and found that
our data are superimposed on the theoretical curve for
tetramers (Figure 6D).
The effect of ligand efﬁcacy on b2AR oligomerization
We examined the effects of three classes of GPCR drugs: a full
agonist (isoproterenol), a neutral antagonist (alprenolol) and
an inverse agonist (ICI) on FRETefﬁciency between different
labelling sites. Upon treatment with saturating amounts
(10mM) of the full agonist isoproterenol, a small, but sig-
niﬁcant, increase in FRETwas observed between TM6 and H8
(Figure 7A and Table II; Po0.05). At saturating concentra-
tions (500nM), alprenolol produced a similar result between
TM6 and H8 (Figure 7A and Table II; Po0.05). It is not
possible to say if these small changes are due to subtle
changes in the relative arrangement of protomers, or small
conformational changes in the receptor.
In contrast to the small changes observed with the agonist
and neutral antagonist, much larger changes were observed
following exposure to the inverse agonist ICI (Figure 7A and
Table II). Inverse agonists include many compounds that
were originally classiﬁed as antagonists, ligands that
occupy the orthosteric binding site, but do not alter receptor
function. Instead, inverse agonists inhibit basal agonist-in-
dependent activity exhibited by many GPCRs, including the
b2AR (Galandrin and Bouvier, 2006). Interestingly, at a
saturating concentration (500nM) of ICI, signiﬁcant changes
in FRET efﬁciency were observed for four of the six
labelling pairs (Figure 7A and Table II). The ICI-induced
changes in FRET reach a maximum at 10min
(Supplementary Figure 4).
The changes in FRET observed with ICI could reﬂect
changes in the orientation of protomers or the number of
protomers in the oligomeric complex. However, these
changes could also be due to ligand-induced changes in the
Table II FRET efﬁciencies in the absence of ligand and upon binding of agonist, neutral antagonist or inverse agonist
a
b2AR region No ligand±s.e.m. +Isoproterenol±s.e.m. P-value +Alprenolol±s.e.m. P-value +ICI 118,551±s.e.m. P-value
ICL-1/ICL-1 30.26±1.2 31.43±0.4 0.45 29.72±4.1 0.86 34.86±1.4 0.043*
TM-6/TM-6 16.73±1.3 17.71±2.1 0.64 21.48±0.8 0.23 27.67±2.0 0.005**
H-8/H-8 26.85±0.8 29.56±1.1 0.06 31.40±3.5 0.07 28.33±1.8 0.418
ICL-1/TM-6 24.58±2.3 22.26±0.4 0.56 27.82±6.1 0.54 30.00±4.6 0.269
ICL-1/H-8 24.08±1.6 23.71±0.7 0.91 26.87±4.8 0.49 35.33±2.4 0.006**
TM-6/H-8 30.98±0.7 35.27±1.5 0.01* 33.63±0.2 0.05* 25.33±2.0 0.005**
aFRETefﬁciencies were calculated as described under Materials and methods. Data represent the mean±s.e.m. of at least three independent
experiments. P-values refer to statistical comparisons between no ligand and three different ligands: isoproterenol, alprenolol and ICI 118,551.
*Po0.05; **Po0.005.
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Figure 6 Speciﬁcity of b2ARoligomerization as assessed by FRETsaturation. FRETsaturation involved varying the ratio of Cy5- to Cy3-labelled
b2ARs over a range of 1:1 to 10:1 (Cy5:Cy3), while the overall b2AR concentration was kept constant. Saturable FRET is observed for ICL1/ICL1
(A), TM6/TM6 (B) and H8/H8 (C). FRET measurements were performed and calculated as described in the Supplementary data. Data represent
the mean±s.e.m. of at least three independent experiments. (D) FRETsaturation data from all three constructs (A–C above) was normalized to
maximal FRETefﬁciency and then averaged and plotted together with theoretical curves (dashed lines) for dimer, trimer, tetramer and higher-
order oligomer that were generated using equation (1) in the Supplementary data.
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ﬂuorophore or the polarity of its environment. We, therefore,
examined the effect of isoproterenol and ICI on the intensity
of the ﬂuorescence and on the anisotropy of the ﬂuorophores
in labelled receptors. For both Cy3- and Cy5-labelled b2AR
reconstituted individually, treatment with either isoprotere-
nol or ICI did not induce signiﬁcant changes in the intensity
of the ﬂuorescence (data not shown) or anisotropy of the
ﬂuorophores, suggesting that the change in FRETefﬁciencies
observed upon ICI treatment are not a result of conforma-
tional changes in protomers (Supplementary Figure 5).
The ICI-induced changes in FRETefﬁciency may be attrib-
uted to several additional factors: reorientation of protomers
in the oligomers, a tighter packing of the protomers, an
increase in the temporal stability of the oligomers (assuming
there is an equilibrium between monomers and oligomers),
and an increase in the stoichiometry of the oligomeric state
(e.g., going from dimers or tetramers to higher-order oligo-
mers). To distinguish between these possibilities, we per-
formed FRET saturation in the presence and absence of ICI,
alprenolol or isoproterenol. Samples were incubated with
ligands for 30min at room temperature and measurements
were taken. Results show that in the presence of ICI the
saturation curve is more similar to a model for higher-order
oligomers, while alprenolol and isoproterenol appear to
have no effect on the apparent oligomeric state of the
receptor (Figure 7B). Higher-order oligomerization was also
observed for the inverse agonists carazolol and carvedilol
(Figure 7D).
Cross-linking was used to further address the state of
multimeric assembly of the b2AR. We used Bis(NHS)PEO5,
a homobifunctional cross-linker with a spacer length of
21.7A ˚ that covalently modiﬁes e-amines of lysine residues
and a-amine groups at the N-termini, effectively trapping
receptors that come within interacting distances. Although
concerns have been raised about the potential for cross-
linkers to trap transiently interacting proteins (Brett and
Findlay, 1979; Downer, 1985; Medina et al, 2004), it is evident
that pre-incubation of samples with ICI leads to more
extensive cross-linking and trapping of higher-order oligomers
of reconstituted b2AR when compared with the unliganded,
the agonist and the antagonist treated samples (Figure 7C and
Supplementary Figure 6). Taken together, these results
s u g g e s tt h a tt h eb2AR forms higher-order oligomers in the
presence of the inverse agonists ICI, carazolol and carvedilol.
To investigate the effect of ICI on the stability of interac-
tions between protomers, we monitored FRET following
addition of 0.2% DDM, a concentration of detergent that
solubilizes the vesicles. We found that the decline in FRET
following the addition of detergent was slower and less
complete in samples pre-incubated with ICI compared with
unliganded samples (Supplementary Figure 7, Po0.05),
providing evidence that ICI also stabilizes interactions
between protomers.
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Figure 7 b2AR oligomers are regulated by inverse agonists. (A) Treatment of FRETsamples with saturating amounts of the inverse agonist ICI
118,551, agonist isoproterenol and neutral antagonist alprenolol. (B) FRET saturation in the presence of ligands. Isoproterenol and alprenolol
led to no observable difference from the unliganded FRETsaturation curve, whereas ICI 118,551 yielded to a curve that is more consistent with
higher-order oligomers. (C) Cross-linking of reconstituted Cy5-labelled b2AR samples in the presence or absence of isoproterenol or ICI 118,551
was carried out as described in the Supplementary data. (D) FRET saturation in the presence of the inverse agonists carvedilol (red) and
carazolol (green). All data are reported as mean±s.e.m. (A, B, D) or are representative of at least three independent experiments (C).
*( Po0.05) and ** (Po0.005).
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To investigate the effect of G protein coupling on oligomer-
ization, we performed FRET saturation experiments by
reconstituting b2AR with a three-fold molar excess of puriﬁed
Gs heterotrimer (Figure 8). This concentration of G protein
was chosen to ensure that sufﬁcient G protein would be
incorporated into vesicles while having a minimal effect on
the reconstitution. The inclusion of Gs did not alter the
orientation of the b2AR as determined by the susceptibility
to PNGase F (Figure 8A). We observed a statistically signiﬁ-
cant (Po0.008) decrease in FRET saturation in the presence
of Gs as compared with reconstitutions in the absence of Gs
(Figure 8B) for Cy5/Cy3 of 0.25, 0.5 and 1. To determine
whether the effect of Gs on FRET saturation was due to
nonspeciﬁc effects of reconstituting with another mem-
brane-associated protein, we performed FRET saturation of
b2AR in the presence of Gs and GTPgS, which uncouples
b2AR and Gs. As shown in Figure 8C, the presence of GTPgS
increases, in a statistically signiﬁcant manner (Po0.04),
FRET saturation to the values observed for b2AR alone.
To estimate the fraction of b2AR that couples to Gs under
these reconstitution conditions, we labelled C265 at the
cytoplasmic end of TM6 with mBBr, an environmentally
sensitive ﬂuorescent probe. We previously showed that max-
imal coupling of Gs to b2AR reconstituted into HDL particles
results in a decrease in the ﬂuorescence intensity and an
18-nm shift in the maximal emission wavelength (lMAX)o f
mBBr–b2AR (mBBr–b2AR; Yao et al, 2009). As shown in
Figure 8D, under reconstitution conditions used for FRET
saturation experiments, Gs induced a decrease in intensity
and a 4-nm shift in lMAX of mBBr–b2AR relative to the same
reconstitution in the presence of GTPgS. Based on the shift of
lMAX we estimate that approximately 20% of the reconsti-
tuted b2AR is coupled to Gs.
Discussion
Receptor dimerization plays an essential role in the function
of Family C GPCRs (Margeta-Mitrovic et al, 2000; Pin et al,
2005). However, the role of oligomerization for Family A
(rhodopsin-like) GPCRs is less clear. It has been shown that
monomeric rhodopsin and b2AR can activate their respective
G proteins (Bayburt et al, 2007; Ernst et al, 2007; Whorton
et al, 2007). Yet, there is convincing evidence from a variety
of experimental approaches that the b2AR and many other
Family A GPCRs exist as dimers or oligomers in the plasma
membrane. Most compelling are studies that apply FRETand/
or BRET technology to receptors tagged with ﬂuorescent
proteins and expressed in cultured cells (Angers et al, 2000;
Mercier et al, 2002; Milligan and Bouvier, 2005; Guo et al,
2008), as well as studies using disulphide cross-linking to
trap interactions in cell membranes to map the interface
between protomers (Guo et al, 2003, 2005, 2008; Klco et al,
2003). Characterization of the structure (protomer organiza-
tion) and dynamics of GPCR oligomers is challenging and will
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β2AR + Gs  Figure 8 Effect of the G protein Gs on FRETsaturation of Cy5- and
Cy3-labelled b2AR. FRET saturation was performed by varying the
ratio of Cy5- to Cy3-labelled b2AR-R333C over a range of 1:4 to 4:1
(Cy5:Cy3), while the overall b2AR concentration was kept constant.
Puriﬁed Gs heterotrimer was added at a molar ratio of 3 Gs:1 b2AR
before reconstitution. (A) The inclusion of Gs in the reconstitution
did not alter the orientation of b2AR in vesicles as determined by the
susceptibility of reconstituted b2AR to PNGase F (see Figure 3C).
FRET saturation was signiﬁcantly lower in the presence of Gs
compared with b2AR alone (B)o rb2AR and Gs with 10mM GTPgS
(C). (D) b2AR was labelled on C265 at the cytoplasmic end of TM6
with mBBr–b2AR and reconstituted with Gs under the same condi-
tions that were used for FRETsaturation experiments. Gs induced a
decrease in intensity and a 4-nm shift in lMAX of mBBr–b2AR
relative to the same reconstitution in the presence of GTPgS.
A two-way ANOVA was used to compare FRET values for b2AR,
b2ARþGs and b2ARþGsþGTPgS at the different Cy5:Cy3 ratios. A
posteriori statistical analysis showed signiﬁcant decrease in FRET
between b2AR and b2ARþGs (Po0.008), and a signiﬁcant increase
in FRET between b2ARþGs and b2ARþGsþGTPgS( Po0.04) for
all Cy5:Cy3 ratios except 2 and 4. No statistical differences are
found between b2AR and b2ARþGsþGTPgS.
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approaches. In an effort to provide additional structural
insight into the organization, stability and regulation of
GPCR oligomers by ligands, we used FRET to study oligo-
merization of puriﬁed b2AR site speciﬁcally labelled with
relatively small ﬂuorescent probes and reconstituted into a
model lipid bilayer. Our results show that monomeric b2ARs
oligomerize spontaneously upon reconstitution into lipid
bilayers in the absence of other cellular chaperones or
scaffold proteins. FRET saturation studies suggest that the
oligomers consist of more than two protomers, and are
probably tetramers. Agonists have little effect on b2AR oligo-
merization, whereas inverse agonists appear to promote
higher-order oligomerization and stabilize the oligomers
against dissolution by detergent.
Spontaneous oligomerization of the b2AR in model lipid
membranes
In a cell membrane, proteins associate in a complex lipid
environment involving mixtures of cholesterol and lipids
having different polar groups, alkyl chain lengths and alkyl
chain saturation. Moreover, the lipid composition of outer
and inner membrane layers is different, and there may be
distinct lipid domains that regulate the function of associated
membrane proteins (Allen et al, 2007). b2AR oligomers have
been observed to form during biosynthesis in the endoplas-
mic reticulum (Salahpour et al, 2004), suggesting that
chaperones and other cellular proteins may also be involved
in the assembly and/or maintenance of oligomers for some
GPCRs. For example, oligomerization of the opioid receptor
has been shown to depend on the G protein Gi (Law et al,
2005). Nevertheless, our results show the strong tendency for
puriﬁed b2AR to oligomerize spontaneously in a model lipid
bilayer, and suggest that b2AR oligomerization is an intrinsic
property of the receptor and does not require other cellular
proteins or a speciﬁc lipid environment. However, we cannot
exclude the possibility that oligomerization in vivo is regu-
lated in some way by cellular proteins or speciﬁc lipid
environments. It should be noted that rhodopsin, neurotensin
receptor 1 and muscarinic receptors have also been observed
to oligomerize following reconstitution into synthetic lipid
bilayers (Mansoor et al, 2006; Ma et al, 2007; Harding et al,
2009), suggesting that spontaneous oligomerization might be
an intrinsic property of Family A GPCRs.
Following puriﬁcation from insect cell membranes, b2ARs
exist as pure monomers in detergent solution (Whorton et al,
2007). Our reconstitution experiments use a simple model
lipid bilayer composed of DOPC and CHS (DOPC/CHS).
In this environment we observe normal ligand binding prop-
erties and efﬁcient G protein activation. The high degree of
homogenous orientation of receptors in this lipid bilayer
model suggests that there must be a non-random mechanism
that controls receptor insertion. While the mechanism for this
is unknown, preferential orientation has also been observed
with reconstitution of rhodopsin, although in this case re-
ceptor was oriented preferentially with the N-terminus in the
inside of the vesicle (Niu et al, 2002). Isopycnic density
centrifugation experiments and EM images (Figure 3) show
that reconstitution using size-exclusion chromatography
yields a homogenous distribution of receptors into lipid
vesicles of an average diameter of 83nm and an average
surface area of approximately 21600nm
2. Under our recon-
stitution conditions, we estimate that there are 50–60 b2AR
molecules per vesicle. Based on the crystal structure of the
b2AR, we can calculate that the surface area occupied by a
single receptor is approximately 16nm
2. Therefore, receptors
occupy less than 10% of the surface area of the vesicle,
suggesting that the FRET we observe is not the result of
nonspeciﬁc interactions due to high receptor density. To
further exclude the possibility of nonspeciﬁc oligomerization,
we reconstituted receptors at a 10-fold higher lipid-to-protein
ratio and found no signiﬁcant decrease in FRET efﬁciency
(Figure 5B–D, P40.05).
Organization and stability of b2AR oligomers
Our reconstitution system, as well as current cell-based
methods, is limited in the ability to precisely deﬁne the
structure and stoichiometry of oligomers. Nevertheless,
recent evidence from resonance energy transfer studies,
cysteine cross-linking and ﬂuorescence recovery after photo-
bleaching (FRAP) studies suggest that the D2 dopamine
receptor and the b2AR form higher-order oligomers (tetra-
mers or greater) (Guo et al, 2008; Dorsch et al, 2009). Data
from FRET studies can provide insight into the orientation of
protomers within these oligomers. However, the following
facts should be taken into account. First, while Cy3 and Cy5
are small relative to ﬂuorescent and luminescent proteins,
they are still large compared with amino acids and have
relatively long ﬂexible linkers tethering them to cysteine
(Figure 9A). As such, their precise orientation in the protein
is not known and has been estimated by computational
techniques. Second, both the distance between ﬂuorophores
and the orientation of ﬂuorophores inﬂuence FRET. The
orientation factor becomes a concern for highly constrained
ﬂuorophores; however, this probably is not the case here,
since the anisotropy values that we observe experimentally
for Cy3 and Cy5 are similar to those reported for free
ﬂuorophores in solution (Kobitski et al, 2007), and these
values are not inﬂuenced by ligands. Third, as discussed
below, the oligomers may be dynamic. While the predomi-
nant form may be a tetramer, these may exist in equilibrium
with monomers, dimers and higher-order oligomers. Finally,
in a tetramer several combinations of donor/acceptor pairs
(0 donors, 4 acceptors; 1 donor, 3 acceptors; etcy) are
possible. In such a system, the measured FRET signal will
be the combination of all the individual energy transfers
between every possible donor/acceptor pair, which compli-
cates the analysis of the measured FRETsignal, and thus, the
estimation of protomer orientation in the tetramer.
Notably, saturation experiments (Figure 6) result in a
much simpler system, composed mostly of tetramers with
one donor and three acceptors. This system dramatically
reduces the number of energy transfer combinations and
simpliﬁes the analysis of FRET efﬁciencies. These values are
used to propose possible monomer orientations within the
tetramer. In FRET saturations studies, the greatest energy
transfer is observed for H8/H8 and smallest for TM6/TM6
(Figure 6B and C). These results are compatible with arrange-
ments of oligomers involving a TM1 interface (Figure 9C)
previously described for the D2 dopamine receptor and
rhodopsin (Liang et al, 2003; Guo et al, 2008). In contrast,
an arrangement that would place TM6/TM6 ﬂuorophores in
close proximity (Figure 9B) is not compatible with the lowest
FRET efﬁciency observed for this pair (Figure 6B).
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matical model for tetramers (Figure 6D), our results are
compatible with a dynamic equilibrium where a fraction of
b2AR exists as monomers in equilibrium with higher-order
oligomers, with the average size of the oligomer being a
tetramer. This is in agreement with the observed maximal
FRET saturation values of 30–45% (Figure 6), lower than
would be expected for stable tetramers given that R0 values
for Cy3 and Cy5 range from 37–56A ˚, depending on the
biochemical system under investigation (Mansoor et al,
2006; Massey et al, 2006). Further evidence supporting this
dynamic behaviour is the observation that the afﬁnity of
interactions between protomers is relatively weak outside of
the bilayer environment, as show by the rapid dissociation of
protomers upon the addition of a non-ionic detergent
(Supplementary Figure 7). Recent FRAP studies provide
evidence that D2 dopamine receptors may also exist in a
dynamic equilibrium of monomers and oligomers (Fonseca
and Lambert, 2009). In these studies, oligomers were only
detected by FRAP after receptors formed stable covalent
dimers through oxidative cross-linking of cysteines in TM4.
While a b2AR monomer can activate Gs (Whorton et al,
2007), it is not known whether higher-order oligomers facil-
itate or impair coupling. Oligomers of rhodopsin (Bayburt
et al, 2007) and NT1 receptor (White et al, 2007) couple less
efﬁciently to G proteins than monomers. If higher-order
oligomers impair coupling, the dynamic character of b2AR
oligomers would ensure that a fraction of the b2AR would
exist as monomers or dimers competent for G protein activa-
tion. Under our experimental conditions, the co-reconstitu-
tion of Gs with b2AR was associated with a small decrease in
FRET saturation that was reversed by GTPgS (Figure 8).
This is compatible with G protein coupling shifting the
equilibrium to lower-order oligomers.
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Figure 9 Schematic representation of possible b2AR oligomers. (A) Cytoplasmic view of the 3D structure of the b2AR (left) and cartoon of this
footprint (right), with the centre of mass of Cy3 depicted as spheres: T66C (green), A265C (blue) and R333C (red). TM6 is depicted in the
inactive conformation (top) and in the proposed active conformation as observed in the structure of opsin (bottom). (B) Receptor
oligomerization involving the surfaces of TMs 4 or/and 5 is not compatible with our FRET results and might sterically prevent movement
of TM6. (C) Our FRETresults suggest an arrangement of protomers involving the TM1 interface. (D) The movement of the cytoplasmic end of
TM6 upon agonist binding repositions the ﬂuorophore outwards in two of the four protomers, and towards H8 in the other two. (E) Treatment
with the inverse agonist ICI probably reduces conformational ﬂuctuations responsible for basal activity, increasing the packing of the
oligomers. (F) ICI may stabilize higher-order oligomers where TM6 is packed into the core of the oligomer, contributing to increase FRET
efﬁciency and possibly the inactive state of the receptor.
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The effect of agonists on oligomerization has been described
for several GPCRs. The results appear to be receptor speciﬁc:
for some receptors no effect is observed, whereas for others,
agonists induce dissociation or association (Angers et al,
2000; Cheng and Miller, 2001; Latif et al, 2002; Zhu et al,
2002; Roess and Smith, 2003; Dorsch et al, 2009). For the
b2AR, Michelle Bouvier’s laboratory reported a small agonist-
induced increase in steady-state BRET; however, they con-
cluded that this could be due to a small change in the steady-
state oligomers or due to conformational changes in indivi-
dual protomers (Angers and Bouvier, 2000). In subsequent
BRET saturation studies from this laboratory (Mercier et al,
2002) and ﬂuorescence recovery after photobleaching studies
from the Bu ¨nemann laboratory (Dorsch et al, 2009), no
signiﬁcant agonist-induced effect was observed. Our
results with the full agonist (isoproterenol) are in agreement
with these cell-based studies. Isoproterenol causes a rela-
tively minor change in intermolecular FRET, with the only
signiﬁcant change occurring in the TM6/H8 FRET pair
(Figure 7A and Table II), but no change in FRET saturation
(Figure 7B). The results are in agreement with the model
depicted in Figure 9C and D where agonists induce a change
in protomer conformation, but not oligomerization. We have
previously shown signiﬁcant agonist-induced movement of
TM6 (Gether et al, 1997; Ghanouni et al, 2001a,b; Yao et al,
2006) consistent with relatively large conformational changes
observed in rhodopsin by DEER spectroscopy (Altenbach
et al, 2008), and from the crystal structure of opsin (Park
et al, 2008; Scheerer et al, 2008). Assuming a tetramer, the
movement of the cytoplasmic end of TM6 away from TM3
(Park et al, 2008) (Figure 9A) locates the ﬂuorophore at-
tached to TM6 towards the periphery in two of the four
protomers, and towards H8 in the other two (Figure 9D).
Thus, the symmetric movement of TM6 in the tetramer,
inwards and outwards, explains the minor changes in
intermolecular FRET of TM6/TM6 observed upon agonist
binding. In addition, the inward movement of TM6 towards
H8 is compatible with the changes occurring in the TM6/H8
FRET pairs. Therefore, protomer packing does not appear to
interfere with conformational changes involving TM6.
In agreement with this, agonist-induced movement of the
cytoplasmic end of TM6, as detected by an environmentally
sensitive ﬂuorophore covalently bound to C265, is similar
for b2AR monomers (reconstituted into HDL particles) and
oligomers (reconstituted into phospholipids vesicles)
(Supplementary Figure 8).
We were surprised to see that the most dramatic changes in
intermolecular FRET were observed on exposure to the
inverse agonist ICI. Most notable are increases in FRET
for TM6/TM6 and ICL1/H8 (Table II and Figure 7A).
Fluorescence studies on monomeric b2AR may provide us
with the link between the effect of an inverse agonist on the
structure of the monomer and the process of oligomerization.
We have previously shown that ICI does not induce major
rearrangements in the structure of the monomer, but may
reduce normal conformational ﬂuctuations responsible for
basal activity (Yao et al, 2006, 2009). We speculate that this
inherent ﬂexibility may interfere with higher-order packing of
the oligomers. Thus, the more constrained structure of the
inverse agonist-bound receptor may be more compatible with
closer packing of protomers within a tetramer (Figure 9E),
a higher-order packing (Figure 9F) or more stable b2AR
oligomers with fewer monomers. It has been observed that
oligomers of rhodopsin (Bayburt et al, 2007) and NT1 recep-
tor (White et al, 2007) couple less efﬁciently to G proteins
than monomers; therefore, higher-order packing induced by
the inverse agonist may restrict access of receptor to G
protein. However, this higher-order packing is not required
for the inverse agonist effect, as an inverse agonist can
efﬁciently prevent coupling of monomeric b2AR to Gs (Yao
et al, 2009). It is likely that a combination of all three effects
is responsible for the ICI-induced FRET changes. The in-
creased stability of oligomers against dissociation by deter-
gent in the presence of ICI (Supplementary Figure 7) is in
agreement with closer packing of protomers, while FRET
saturation (Figure 7B and Supplementary Figure 5) and
cross-linking experiments (Figure 7C and Supplementary
Figure 6) are in agreement with higher-order oligomers.
Our results are consistent with a rearrangement of the
oligomerization interfaces that has been observed for the
dopamine D2 receptor upon inverse agonist binding (Guo
et al, 2005), and the observation of higher-order packing of
the inactive state of rhodopsin in rod outer segment mem-
branes (Liang et al, 2003). The functional consequence of this
higher-order oligomerization is not known, but could impair
coupling of the b2AR to Gs, or be involved in the coupling of
the b2AR to other signalling pathways. Interestingly, both ICI
and carvedilol have been shown to activate MAPK through a
G protein-independent, arrestin-dependent signalling path-
way (Galandrin and Bouvier, 2006; Wisler et al, 2007). The
dramatic effects of ICI on oligomerization might be expected
to inﬂuence ICI binding afﬁnity or cooperativity; however, no
differences in ICI binding properties were observed between
b2AR monomers (reconstituted into HDL particles) and
oligomers (reconstituted into phospholipids vesicles) (data
not shown).
In conclusion, we ﬁnd that the b2AR is capable of forming
speciﬁcally oriented multimeric assemblies in a model lipid
bilayer in the absence of other cellular proteins, complement-
ing previous studies of Family A GPCRs. Although we cannot
determine the oligomeric interfaces with precision, our
results are compatible with models proposed for several other
Family A GPCRs, where oligomerization involves primarily the
TM1/H8 interface. Most unexpected was the observation that
inverse agonists promoted higher-order b2AR oligomerization.
This may alter access to other signalling proteins, providing
insight into the ability of inverse agonists to inhibit basal G
protein signalling or in promoting G protein-independent activa-
tion of MAPK pathways. These results suggest a potential
structural link between the stabilizing effects of inverse agonists
on b2AR monomers and the assembly of oligomers in lipid
bilayers.
Materials and methods
Materials
Cy3–maleimide and Cy5–maleimide were both obtained from
Amersham Biosciences. [
3H]-DHA and [
35S]-GTPgS were purchased
from Amersham and Perkin Elmer, respectively. All drugs tested
were purchased from Sigma. The Bis(NHS)PEO5 homobifunctional
cross-linker and NHS-PEO4-Biotin were purchased from Pierce.
Engineering of single-cysteine b2AR mutants
Site-directed mutagenesis of the b2AR was performed by using the
human b2AR cDNA containing a FLAG epitope at the N-terminus as
b2-Adrenoceptor oligomers
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cysteines (out of 13 native cysteines) in the b2AR were mutated as
follows: C77V, C265A, C327S, C378A and C406A to generate a D5
background (Gether et al, 1997). Mutations for the three single-
reactive cysteine constructs (T66C, A265C and R333C all in D5) in
these studies were carried out by PCR mutagenesis with Pfu
polymerase (Stratagene, La Jolla, CA). The mutated cDNAwas then
digested with appropriate enzymes and cloned into the pFastBac1
(Invitrogen) vector. All constructs were conﬁrmed by restriction
enzyme analysis and DNA sequencing.
Expression and puriﬁcation of b2AR from Sf9 insect cells
Sf9 insect cells were grown at 271C in suspension cultures in ESF-
921 medium (Expression Systems, CA) supplemented with 0.5mg/
ml gentamicin. The Bac-to-Bac Baculovirus Expression System
(Invitrogen) was used for generating baculovirus for each of the
b2AR constructs. b2AR expression was accomplished by infecting
Sf9 cells at a density of B3 10
6cells/ml for B48h. Cells now
expressing receptor, as assessed by immunoﬂuorescence, were
harvested by centrifugation (15min at 5000g). Cell pellets were
stored at  801C prior to puriﬁcation. b2AR from Sf9 cells was
puriﬁed using a three-step puriﬁcation procedure involving M1 anti-
FLAG column, followed by alprenolol–Sepharose afﬁnity column
and a second M1 anti-FLAG column as described previously
(Swaminath et al, 2005; Granier et al, 2007). Saturation binding of
the antagonist [
3H]-DHA was used to determine the concentration
of functional puriﬁed b2AR. Detailed protocols are found in
Supplementary data.
Lipid preparation
DOPC 18:1 phospholipid (Avanti Polar Lipids Inc.) and CHS
(Steraloids, Inc.) were mixed and dissolved in chloroform to form
a stock solution of lipids at a concentration of 20 and 10mg/ml,
respectively. DOPC and cholesterol were added to a glass vial, with
DOPC at a 10-fold molar excess, and chloroform was evaporated
under a ﬁne stream of argon. The lipids were then further dried
under vacuum for 1h. The lipids were resuspended in Buffer G
(20mM HEPES, 100mM NaCl, 1% octylglucoside, pH 7.5), vortexed
and sonicated for 1h in an ice water bath. The lipid mixture was
stored at  801C.
Fluorescence labelling and reconstitution of puriﬁed receptors
Puriﬁed b2ARs were labelled with two equivalents of either Cy3–
maleimide or Cy5–maleimide (Amersham Biosciences) for 15min
at 41C. Labelling reactions were quenched by adding a ﬁnal of 1mM
L-cysteine.
b2AR was reconstituted as described previously (Swaminath
et al, 2005). Brieﬂy, for each mutant generated, 300-ml samples were
prepared containing the following receptors for reconstitution:
either Cy3–b2AR alone, Cy5–b2AR alone or both Cy3–b2AR and
Cy5–b2AR. The amount of both labelled receptors and lipids used
for reconstitution varied depending on the lipid-to-receptor ratio.
Either 1000:1 (mol lipid:mol receptor) or 10000:1 (mol lipid:mol
receptor) conditions were used. The lipid/receptor mixture, plus
reconstitution buffer to 300ml, was mixed and placed on ice for 2h.
Vesicles were allowed to form by removing detergent on a
Sephadex G-50 (ﬁne) column (25 0.8cm) using reconstitution
buffer (20mM HEPES, 100mM NaCl, pH 7.5).
To assess the proportion of receptors incorporating into vesicles,
we performed discontinuous sucrose gradients as described
previously for rhodopsin (Mansoor et al, 2006) (see Supplementary
data).
The number of ﬂuorophore molecules per reconstituted receptor
was calculated by using the maximum absorbance of the donor- or
acceptor-labelled receptor. The number of donor or acceptor
ﬂuorophores per b2AR ranged between different preps from 0.4 to
0.8 for all three constructs (Supplementary Table 1).
Fluorescence spectroscopy
Experiments were performed at 251C with a SPEX FluoroMax-3
spectroﬂuorometer (excitation and emission bandpass of 2nm,
S/R acquisition mode). The ﬁnal concentration of b2AR used for
spectroscopy was typically B20nM.
For FRET experiments, spectra were taken from receptors
labelled with donor (Cy3) and reconstituted together with receptors
labelled with acceptor (Cy5) at the various cysteine mutants
generated. Spectra of receptors labelled with only the acceptor
ﬂuorophore and reconstituted alone were also taken. For each type
of receptor, two types of emission scans were acquired. The ﬁrst
emission scan (donor scan) acquired used the excitation maximum
for the donor ﬂuorophore Cy3 (lex¼550nm). The second emission
scan (acceptor scan) used the excitation maximum for the acceptor
ﬂuorophore Cy5 (lex¼649nm). For testing the effects of b2AR
ligands, samples±drug were mixed and incubated 20min at RT.
Three separate samples were used for testing each type of drug and
individual spectra were acquired and averaged. Removal of
acceptor bleed-through and correction of any drug-induced acceptor
ﬂuorescence intensity changes were carried out and described
in detail previously (Granier et al, 2007) and are present in
Supplementary data.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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